6.
Aarhus T, Bjornstad F, Wolowczyk C, Larsen K, Rognstad L, Leithaug T
. Synthesis and Development of Highly Selective Pyrrolo[2,3-]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form. J Med Chem. 2023; 66(10):6959-6980.
PMC: 10226129.
DOI: 10.1021/acs.jmedchem.3c00428.
View
7.
Kurup S, McAllister B, Liskova P, Mistry T, Fanizza A, Stanford D
. Design, synthesis and biological activity of N-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. J Enzyme Inhib Med Chem. 2017; 33(1):74-84.
PMC: 6009956.
DOI: 10.1080/14756366.2017.1376666.
View
8.
Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z
. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)--(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J Med Chem. 2019; 62(13):6083-6101.
DOI: 10.1021/acs.jmedchem.9b00280.
View
9.
Hennequin L, Stokes E, Thomas A, Johnstone C, Ple P, Ogilvie D
. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 2002; 45(6):1300-12.
DOI: 10.1021/jm011022e.
View
10.
Gross K, Seybold P, Murray J, Politzer P
. Comparison of quantum chemical parameters and Hammett constants in correlating pK(a) values of substituted anilines. J Org Chem. 2001; 66(21):6919-25.
DOI: 10.1021/jo010234g.
View
11.
Sun L, Cui J, Liang C, Zhou Y, Nematalla A, Wang X
. Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases. Bioorg Med Chem Lett. 2002; 12(16):2153-7.
DOI: 10.1016/s0960-894x(02)00364-5.
View
12.
Ayala-Aguilera C, Valero T, Lorente-Macias A, Baillache D, Croke S, Unciti-Broceta A
. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. J Med Chem. 2021; 65(2):1047-1131.
DOI: 10.1021/acs.jmedchem.1c00963.
View
13.
Liu M, Shen C, Tang T, Pan C, Liu M, Zhang X
. Palladium-Catalyzed Highly Regioselective C6 Arylation of Pyrrolo[2,3-]pyrimidine Derivatives with Arylboronic Acids. Org Lett. 2023; 25(15):2637-2641.
DOI: 10.1021/acs.orglett.3c00680.
View
14.
Jesumoroti O, Beteck R, Jordaan A, Warner D, Legoabe L
. Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agents. Mol Divers. 2022; 27(2):753-765.
PMC: 9124159.
DOI: 10.1007/s11030-022-10453-1.
View
15.
Reiersolmoen A, Han J, Sundby E, Hoff B
. Identification of fused pyrimidines as interleukin 17 secretion inhibitors. Eur J Med Chem. 2018; 155:562-578.
DOI: 10.1016/j.ejmech.2018.06.019.
View
16.
Laufer S, Domeyer D, Scior T, Albrecht W, Hauser D
. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005; 48(3):710-22.
DOI: 10.1021/jm0408767.
View
17.
Rossini E, Bochevarov A, Knapp E
. Empirical Conversion of p Values between Different Solvents and Interpretation of the Parameters: Application to Water, Acetonitrile, Dimethyl Sulfoxide, and Methanol. ACS Omega. 2019; 3(2):1653-1662.
PMC: 6641400.
DOI: 10.1021/acsomega.7b01895.
View
18.
Boschelli D, Ye F, Wang Y, Dutia M, Johnson S, Wu B
. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem. 2001; 44(23):3965-77.
DOI: 10.1021/jm0102250.
View
19.
Dorel R, Grugel C, Haydl A
. The Buchwald-Hartwig Amination After 25 Years. Angew Chem Int Ed Engl. 2019; 58(48):17118-17129.
DOI: 10.1002/anie.201904795.
View
20.
Yin J, Buchwald S
. Pd-catalyzed intermolecular amidation of aryl halides: the discovery that xantphos can be trans-chelating in a palladium complex. J Am Chem Soc. 2002; 124(21):6043-8.
DOI: 10.1021/ja012610k.
View